CM Life Sciences II and SomaLogic, Inc. have received approval from the SEC for their business combination, with a special meeting for shareholders set for August 31, 2021. The planned transaction is expected to close soon thereafter. SomaLogic reported impressive preliminary revenue of approximately $19.7 million for Q2 2021, marking a 176% increase year-over-year, and $38.6 million for the first half, a 187% increase. Growth is attributed to a return to fee-for-service options, new pharma and research ventures, and royalties.
On August 12, 2021, SomaLogic announced that Melody Harris, its President and COO, has been honored as a 2021 C-Suite Award winner by the Denver Business Journal. This recognition highlights her leadership and contributions to the company's growth and innovation. CEO Roy Smythe praised her ability to develop strong teams and effective business structures. The C-Suite Awards celebrate executives who demonstrate exceptional leadership, risk management, and profitable growth, with Harris being recognized for her pivotal role at SomaLogic.
On August 2, 2021, SomaLogic announced the appointment of Shaun Blakeman as Chief Financial Officer. With over 20 years of experience, Blakeman previously held executive roles at Cantel Medical and Medtronic, strengthening SomaLogic's leadership. CEO Roy Smythe expressed confidence in Blakeman's impact as the company aims to scale its AI-driven proteomics technology. Blakeman holds advanced degrees in economics, applied physics, and business administration, and acknowledged the opportunity to enhance global healthcare outcomes.